-
PharmaTher Is 'One Step Closer To Being A Ketamine Leader' Due To FDA Acceptance
Wednesday, September 27, 2023 - 2:38pm | 429Read More...The Food and Durg Administration (FDA) has accepted specialty biopharma company PharmaTher Holdings’ (OTCQB: PHRRF) new drug application for a racemic ketamine product. What Happened: The so-called goal date for PharmaTher's KETARX drug is April 29, 2024, according to the FDA. From...
-
PharmaTher Aims To Mitigate Ketamine Shortage With New FDA Application
Wednesday, September 6, 2023 - 5:21pm | 477Read More...Specialty biotech company PharmaTher Holdings (OTCQB: PHRRF) reported it has submitted a priority-original Abbreviated New Drug Application (ANDA) for its proprietary racemic ketamine, KETARX, to the FDA. The company expects the agency will perform an expedited review of its ANDA, and ...
-
Valeant Withdraws Prior Guidance, Announces CEO Mike Pearson Will Return To Work Immediately Following Pneumonia Scare
Monday, February 29, 2016 - 8:35am | 250Read More...Shares of Valeant Pharmaceuticals Intl Inc (NYSE: VRX) plunged more than 8 percent early Monday morning after the company issued a business update over the weekend. Valeant confirmed that Michael Pearson will resume his role as CEO, effective immediately. The executive was hospitalized...
